<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04921553</url>
  </required_header>
  <id_info>
    <org_study_id>ET20000258 TRacKING</org_study_id>
    <nct_id>NCT04921553</nct_id>
  </id_info>
  <brief_title>Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)</brief_title>
  <acronym>TRacKING</acronym>
  <official_title>Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This registry will make it possible to describe real life management of patients with rare&#xD;
      actionable fusions and to better understand these cancers. In addition of clinical data from&#xD;
      the medical files, a quality of life questionnaire (QLQ-C30) will be complete at inclusion,&#xD;
      at each new treatment and then every 6 months. The patients will be followed for a period of&#xD;
      at least 2 years after the inclusion.&#xD;
&#xD;
      This TRacKING registry is a European collaborative tool to improve the management of patients&#xD;
      with actionable fusions, by sharing of data from rare tumor indications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Administrative opening of the center&#xD;
&#xD;
        2. Routine identification of a patients harboring a rare actionable fusion&#xD;
&#xD;
        3. Patient's inclusion&#xD;
&#xD;
             -  Signature of written informed consent,&#xD;
&#xD;
             -  Declaration by the physician to the coordinating center (using the &quot;Physician&#xD;
                declaration&quot; form)&#xD;
&#xD;
             -  Completion of the QLQ-C30 questionnaire (at inclusion, at each new treatment and&#xD;
                then every 6 months).&#xD;
&#xD;
        4. Collection of retrospective and prospective data into the e-CRF by a local CRA using&#xD;
           patients' medical files.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2021</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>To describe the survival rate of patients with solid cancers harboring a NTRK fusion or other rare actionable fusion in real-life practice, according to overall survival (OS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Management of patient with actionable fusion</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Treatment scheme : number of line and type of treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to relapse</measure>
    <time_frame>up to 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>after 6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of long-term responders</measure>
    <time_frame>up to 48 months</time_frame>
    <description>long term responders =: &gt; 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life of patient</measure>
    <time_frame>After 6, 12, 18, 24, 30, 36, 42, 48 months</time_frame>
    <description>To evaluate patient-reported outcomes concerning individual QoL according to QLQ-C30 (EORTC Quality of Life questionnaires)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to relapse for fusion-targeting treatments</measure>
    <time_frame>up to 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival for patient treated by fusion-targeting treatments</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS for patient treated by fusion-targeting treatments</measure>
    <time_frame>After 6, 12, 24 months of treatment by fusion targeting treatments</time_frame>
    <description>Progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of long-term responders for patient treated by fusion-targeting treatments</measure>
    <time_frame>up to 48 months</time_frame>
    <description>&gt; 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life of patient treated by fusion-targeting treatments</measure>
    <time_frame>After 6, 12, 18, 24, 30, 36, 42, 48 months of fusion-targeting treatments</time_frame>
    <description>using QLQC30 (EORTC Quality of Life questionnaires)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety : Nature of adverse reaction (for treatment targeting a fusion)</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Using Common Terminology Criteria for Adverse Events (CTCAE) V5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety : Frequency of adverse reaction (for treatment targeting a fusion)</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Using Common Terminology Criteria for Adverse Events (CTCAE) V5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety : Severity of adverse reaction (for treatment targeting a fusion)</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Using Common Terminology Criteria for Adverse Events (CTCAE) V5.0.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Cancer</condition>
  <condition>Cancer Metastatic</condition>
  <condition>NTRK Gene Fusion Overexpression</condition>
  <condition>NTRK Family Gene Mutation</condition>
  <condition>ATIC-ALK Fusion Protein Expression</condition>
  <condition>ALK Fusion Protein Expression</condition>
  <condition>BCR-FGFR1 Fusion Protein Expression</condition>
  <condition>ROS1 Gene Translocation</condition>
  <condition>COL1A1-PDGFB Fusion Protein Expression</condition>
  <condition>RET Gene Translocation</condition>
  <condition>Gene Fusion</condition>
  <condition>ROS Gene Translocation</condition>
  <condition>BRAF Gene Rearrangement</condition>
  <condition>FGFR2 Gene Translocation</condition>
  <condition>FGFR3 Gene Translocation</condition>
  <condition>NTRK1 Gene Translocation</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection and quality of life questionnaire</intervention_name>
    <description>Data collection from the medical file&#xD;
Quality of life questionnaire (QLQC30) at inclusion, at each change of treatment and then every 6 months</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with histologically-confirmed cancer that harboring a rare actionnable fusion,&#xD;
        treated in a European center&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with histologically-confirmed cancer&#xD;
&#xD;
          -  Patient harboring a rare actionable fusion (see Appendix 1),&#xD;
&#xD;
          -  Availability of clinical and demographic data, information on treatment and clinical&#xD;
             outcome.&#xD;
&#xD;
          -  Adult, â‰¥18 years old,&#xD;
&#xD;
          -  Patient should understand, sign and date the written voluntary informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jean-Yves BLAY, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julien Bollard</last_name>
    <phone>04 78 78 28 28</phone>
    <email>julien.bollard@lyon.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandra BIETTE</last_name>
    <phone>04 78 78 28 28</phone>
    <email>alexandra.biette@lyon.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Andreas LEITNER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Thomas BRODOWICZ</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Masaryk Memorial Cancer Institute (Masarykuv Onkologicky Ustav)</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jana HalÃ¡mkovÃ¡</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ninna Aggerholm</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Jean Minjoz</name>
      <address>
        <city>BesanÃ§on</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Loic CHAIGNEAU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antoine ITALIANO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Georges Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alice HERVIEU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Nicolas PENEL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>ValÃ©rie LE BRUN LY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre LÃ©on BÃ©rard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien Bollard</last_name>
      <email>julien.bollard@lyon.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>Alexandra Biette</last_name>
      <email>alexandra.biette@lyon.unicancer.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Yves BLAY, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille (AP-HM)</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marie Eve GARCIA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Esma SAADA-BOUZID</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah WATSON</last_name>
    </contact>
    <investigator>
      <last_name>Sarah WATSON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aphp - Hopital de La Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jean-Philippe SPANO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aphp - Hopital Cohin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Pascaline BOUDOU-ROUQUETTE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aphp - Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jean-Pierre LOTZ</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>CÃ©cile GUILLEMET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Thibaud VALENTIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;HÃ¤mato-Onkologischer Studienkreis MVZ am Klinikum Aschaffenburg / Onkologie&quot;</name>
      <address>
        <city>Aschaffenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Manfred WELSLAU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CharitÃ© - UniversitÃ¤tsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jalid SEHOULI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;Klinik fÃ¼r Innere Medizin III, HÃ¤matologie, Onkologie Klinikum Chemnitz&quot;</name>
      <address>
        <city>Chemnitz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mathias HANEL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;Medizinische Klinik 1- Gastroenterologie, Hepatologie, Pneumologie UniversitÃ¤tsklinikum Frankfurt&quot;</name>
      <address>
        <city>Frankfurt am main</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jorg TROJAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;HÃ¤matologisch-onkologische Ambulanz UniversitÃ¤tsklinikum Halle&quot;</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Haifa Kathrin Al-Ali</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;Klinik fÃ¼r Gastroenterologie, Hepatologie und Infekt UniversitÃ¤tsklinikum Magdeburg&quot;</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marino Venerito</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mannheim University Medical Center (UniversitatsMedizin Mannheim)</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Bernd KASPER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;Medizinische Klinik und Poliklinik III LMU - Klinikum der UniversitÃ¤t MÃ¼nchen&quot;</name>
      <address>
        <city>MÃ¼nchen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Volker HEINEMANN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;Klinik fÃ¼r Innere Medizin III, HÃ¤matologie, Onkologie SÃ¼dharzklinikum&quot;</name>
      <address>
        <city>Nordhausen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Hans-Heinrich WOLF</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum TÃ¼bingen Medizinische UniversitÃ¤tsklinik;</name>
      <address>
        <city>TÃ¼bingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Constantin Roder</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital WÃ¼rzburg (UniversitÃ¤tsKlinikum WÃ¼rzburg)</name>
      <address>
        <city>WÃ¼rzburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Volker KUNZMANN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera - Universitaria - Policlinico S Orsola-Malpighi Univertsita di Bologna</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Maria Abbondenza PANTALEO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Toni IBRAHIM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Neurologico Carlo Besta</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marica EOLI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale San Raffale</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alice BERGAMINI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CRTR-AOU Federico II</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mario GIULIANO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria Cita della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Riccardo SOFFIETTI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ellen KAPITEIJN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska Curie National Research Institute of Oncology</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Iwona LUGOWSKA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology of Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mojca UNK</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario regional Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Javier MARTIN-BROTO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Robin JONES</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>John BRIDGEWATER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 18, 2021</study_first_submitted>
  <study_first_submitted_qc>June 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>actionnable fusion</keyword>
  <keyword>cancer</keyword>
  <keyword>registry</keyword>
  <keyword>European reference network</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

